Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

Mukul Sharma, Graeme J. Hankey, Ḱazunori Toyoda et al.|The Lancet Neurology|2023

Cited by 95